Free Mesothelioma Information Packet

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Sponsored by:Morphotek
Information provided:Morphotek
ClinicalTrials.gov Identifier:NCT00923455

Purpose:


This research is being done to find out if pemetrexed and cisplatin work better when given
together with an experimental drug called MORAb-009 in patients with malignant pleural
mesothelioma.

Condition Intervention Phase
Malignant Pleural Mesothelioma
Drug: MORAb-009 (Amatuximab)
Drug: Pemetrexed
Drug: Cisplatin
Phase 2

Eligibility

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Official Title: An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Additional Details:

Enrollment Size: Both

Gender: 18 Years

Min. Age: N/A

Max. Age: No

Location and Contact Information

United States, Alabama
University of Alabama, Birmingham, Birmingham, Alabama, 35294, United States
Status:

United States, California
University of California, San Diego, La Jolla, California, 92093, United States
Status:

United States, California
UCLA Medical Hematology & Oncology, Los Angeles, California, 90095, United States
Status:

United States, California
University of California, San Francisco, San Francisco, California, 94115, United States
Status:

United States, Colorado
University of Colorado Cancer Center, Aurora, Colorado, 80045, United States
Status:

United States, Delaware
Christiana Care Health System, Newark, Delaware, 19713, United States
Status:

United States, Georgia
Emory University School of Medicine, Atlanta, Georgia, 30322, United States
Status:

United States, Illinois
University of Chicago Medical Center, Chicago, Illinois, 60637, United States
Status:

United States, Maryland
Johns Hopkins University--Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States
Status:

United States, Maryland
NIH/National Cancer Institute, Bethesda, Maryland, 20892, United States
Status:

United States, New York
Columbia University Medical Center, New York, New York, 10032, United States
Status:

United States, West Virginia
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, 26506, United States
Status:

Canada, Ontario
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada
Status:

, G1V 3E6
Hopital Laval, Quebec, PQ, G1V 3E6, Canada,
Status:

, 14165
HELIOS Klinikum Emil von Behring, Berlin, 14165, Germany,
Status:

, 82131
Asklepios Fachkliniken Müchen-Gauting, Gauting, 82131, Germany,
Status:

, 22927
Krankenhaus Großhansdorf, Großhansdorf, 22927, Germany,
Status:

, 21075
Asklepios Klinik Harburg, Hamburg, 21075, Germany,
Status:

, 30625
Medizinsche Hochschule Hannover, Hannover, 30625, Germany,
Status:

, 34376
Fachklinik für Lungenerkrankungen Immenhausen, Immenhausen, 34376, Germany,
Status:

, 81657
Medizinische Klinik (Hämatologie/Onkologie), München, 81657, Germany,
Status:

, 7513 ER
Medisch Spectrum Twente, Enschede, 7513 ER, Netherlands,
Status:

, 3015 CE
Erasmus MC, Rotterdam, 3015 CE, Netherlands,
Status:

, 08025
H. de la Santa Creu i Sant Pau, Barcelona, 08025, Spain,
Status:

, 07014
H. Son Dureta, Palma de Mallorca, 07014, Spain,
Status:

, 31008
Clínica Universitaria de Navarra, Pamplona, 31008, Spain,
Status:

, 08208
Consorci Sanitari Parc Taulí, Sabadell Barcelona, 08208, Spain,
Status:

, 41013
H. Virgen del Rocío, Sevilla, 41013, Spain,
Status:

Last modified: September 01, 2014.